JP2024542777A - 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン - Google Patents

多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン Download PDF

Info

Publication number
JP2024542777A
JP2024542777A JP2024532973A JP2024532973A JP2024542777A JP 2024542777 A JP2024542777 A JP 2024542777A JP 2024532973 A JP2024532973 A JP 2024532973A JP 2024532973 A JP2024532973 A JP 2024532973A JP 2024542777 A JP2024542777 A JP 2024542777A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
binding protein
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542777A5 (https=
Inventor
ダレン、ジェイ、オースティン
アリエノール、シー、バージェス
ニコラス、ピー、バード
マーナ、エイ、モンク
イザベル、ジェイ、プーリケン
メリッサ、エイ、シューマン
キアーラ、ゼッキン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2021/086689 external-priority patent/WO2022136209A1/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2024542777A publication Critical patent/JP2024542777A/ja
Publication of JP2024542777A5 publication Critical patent/JP2024542777A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024532973A 2021-12-03 2022-12-01 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン Pending JP2024542777A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285513P 2021-12-03 2021-12-03
US63/285,513 2021-12-03
EPPCT/EP2021/086689 2021-12-20
PCT/EP2021/086689 WO2022136209A1 (en) 2020-12-22 2021-12-20 Interleukin 5 binding protein dosage regimen
US202263349622P 2022-06-07 2022-06-07
US63/349,622 2022-06-07
PCT/EP2022/084075 WO2023099668A1 (en) 2021-12-03 2022-12-01 Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)

Publications (2)

Publication Number Publication Date
JP2024542777A true JP2024542777A (ja) 2024-11-15
JP2024542777A5 JP2024542777A5 (https=) 2025-12-08

Family

ID=84688427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532973A Pending JP2024542777A (ja) 2021-12-03 2022-12-01 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン

Country Status (5)

Country Link
US (1) US20250042985A1 (https=)
EP (1) EP4440617A1 (https=)
JP (1) JP2024542777A (https=)
CA (1) CA3239667A1 (https=)
WO (1) WO2023099668A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026047072A1 (en) * 2024-08-30 2026-03-05 Glaxosmithkline Intellectual Property Development Limited Medical use
WO2026078117A1 (en) * 2024-10-11 2026-04-16 Glaxosmithkline Intellectual Property Development Limited Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117018188A (zh) 2017-05-26 2023-11-10 葛兰素史密斯克莱知识产权发展有限公司 生物制药组合物和相关方法

Also Published As

Publication number Publication date
CA3239667A1 (en) 2023-06-08
EP4440617A1 (en) 2024-10-09
WO2023099668A1 (en) 2023-06-08
US20250042985A1 (en) 2025-02-06

Similar Documents

Publication Publication Date Title
AU2018253118B2 (en) Treatment of asthma with anti-TSLP antibody
US20210380705A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
JP6995844B2 (ja) アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
EP2777710A1 (en) Methods for administering anti-IL-5 antibodies
KR20220028177A (ko) 류마티스 관절염에 대한 치료
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
EP3185902B1 (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
JP2021523881A (ja) リゲリズマブを使用して慢性特発性蕁麻疹を治療する方法
CA2538737A1 (en) Treatment of respiratory diseases with anti-il-2 receptor antibodies
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
CN118524849A (zh) 用于治疗多血管炎、嗜酸性粒细胞增多综合症、伴有鼻息肉的慢性鼻窦炎嗜酸性粒细胞增多综合症(crswnp)或不伴有鼻息肉慢性鼻窦炎(crssnp)的白细胞介素5结合蛋白给药方案
CA3164126A1 (en) Antibodies for the treatment of chronic graft versus host disease
WO2022136209A1 (en) Interleukin 5 binding protein dosage regimen
JP2017193541A (ja) 関節リウマチを治療するための医薬組成物
CN116635417A (zh) 白介素5结合蛋白给药方案
TW202529803A (zh) 用於治療伴有多血管炎的嗜酸性球性肉芽腫病的ＩＬ－５Ｒ－α抗體
JP2018070473A (ja) 関節リウマチを治療するための医薬組成物
AU2024344855A1 (en) Il-5r-alpha antibodies for treating eosinophilic granulomatosis with polyangiitis
JP2026503045A (ja) Ｔｓｌｐ抗体を使用して喘息を治療するための方法
WO2025096432A1 (en) Treatment of anca-associated vasculitis
WO2025242619A1 (en) Treatment for mucus plugging
KR20220110512A (ko) 인터류킨-17(il-17) 길항제를 사용하여 편평 태선을 치료하는 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128